VeriStrat (R) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib

J. L. Kuiper, J. S. W. Lind, H. J. M. Groen, J. Roder, J. Grigorieva, H. Roder, A. M. C. Dingemans, E. F. Smit

Research output: Contribution to journalArticleAcademicpeer-review

23 Citations (Scopus)
Original languageEnglish
Pages (from-to)1820-1825
JournalBritish Journal of Cancer
Volume107
Issue number11
DOIs
Publication statusPublished - 20 Nov 2012

Keywords

  • lung cancer
  • proteomics
  • erlotinib
  • sorafenib
  • serum biomarker
  • personalised therapy

Cite this

Kuiper, J. L., Lind, J. S. W., Groen, H. J. M., Roder, J., Grigorieva, J., Roder, H., Dingemans, A. M. C., & Smit, E. F. (2012). VeriStrat (R) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib. British Journal of Cancer, 107(11), 1820-1825. https://doi.org/10.1038/bjc.2012.470